Zobrazeno 1 - 10
of 849
pro vyhledávání: '"Mihai Gheorghiade"'
Autor:
Benjamin S. Wessler, Robin Ruthazer, James E. Udelson, Mihai Gheorghiade, Faiez Zannad, Aldo Maggioni, Marvin A. Konstam, David M. Kent
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 11 (2017)
BackgroundHeart failure clinical practice guidelines recommend applying validated clinical predictive models (CPMs) to support decision making. While CPMs are now widely available, the generalizability of heart failure CPMs is largely unknown. Method
Externí odkaz:
https://doaj.org/article/659234cef5114315bcc5565629109367
Effects of Oral Amino Acid Supplements on Functional Capacity in Patients with Chronic Heart Failure
Autor:
Carlo Lombardi, Valentina Carubelli, Valentina Lazzarini, Enrico Vizzardi, Filippo Quinzani, Federica Guidetti, Riccardo Rovetta, Savina Nodari, Mihai Gheorghiade, Marco Metra
Publikováno v:
Clinical Medicine Insights: Cardiology, Vol 2014, Iss 8, Pp 39-44 (2014)
Externí odkaz:
https://doaj.org/article/42479955045445199fed5cc9c5f4cbb5
Autor:
Erik B. Schelbert, Kayla M. Piehler, Karolina M. Zareba, James C. Moon, Martin Ugander, Daniel R. Messroghli, Uma S. Valeti, Chung‐Chou H. Chang, Sanjeev G. Shroff, Javier Diez, Christopher A. Miller, Matthias Schmitt, Peter Kellman, Javed Butler, Mihai Gheorghiade, Timothy C. Wong
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 4, Iss 12, Pp n/a-n/a (2015)
Background Myocardial fibrosis (MF) in noninfarcted myocardium may be an interstitial disease pathway that confers vulnerability to hospitalization for heart failure, death, or both across the spectrum of heart failure and ejection fraction. Hospital
Externí odkaz:
https://doaj.org/article/afb969a8dd7e47bab91058a42339223c
Autor:
Jonathan W. Cunningham, João Pedro Ferreira, Hsiaowei Deng, Stefan D. Anker, William M. Byra, John G.F. Cleland, Mihai Gheorghiade, Carolyn S.P. Lam, David La Police, Mandeep R. Mehra, James D. Neaton, Theodore E. Spiro, Dirk J. van Veldhuisen, Barry Greenberg, Faiez Zannad
Publikováno v:
JACC: Heart Failure. 8:359-368
Objectives This study investigated the effects of a mid-trial protocol amendment requiring elevated natriuretic peptides for inclusion in the COMMANDER-HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, M
Autor:
Olav W. Nielsen, Mihai Gheorghiade, Morten Schou, Gunnar Gislason, Michele Senni, Hans-Dirk Düngen, Bernhard R. Winkelmann, Frank Richard, Savina Nodari, Lars Køber, Michael Becka, Friederike Kanefendt, Christiane Otto
Publikováno v:
Clinical Pharmacology in Drug Development. 8:942-951
The chymase inhibitor fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction (LVD) after acute myocardial infarction (MI). The aim of the study was
Autor:
Kameswari Maganti, James D. Flaherty, John J. Friedewald, Matthew E. Harinstein, Mihai Gheorghiade, Joseph T. Knapper, Michael J. Cuttica, Zankhana Raval, Jayson Rakesh Baman, Ziad A. Ali, M. Abecassis
Publikováno v:
Clin J Am Soc Nephrol
The pretransplant risk assessment for patients with ESKD who are undergoing evaluation for kidney transplant is complex and multifaceted. When considering cardiovascular disease in particular, many factors should be considered. Given the increasing i
Autor:
Ali Ahmed, Gerasimos Filippatos, Stefan D. Anker, Javed Butler, Gregg C. Fonarow, Stephen J. Greene, Mihai Gheorghiade, Catherine N. Marti, Muthiah Vaduganathan, Clyde W. Yancy, James L. Januzzi
Publikováno v:
European journal of heart failure, vol 21, iss 3
Multiple drug classes have shown incremental benefits in heart failure with reduced ejection fraction. Most of these trials were designed to achieve specific doses of the investigational agent. Clinical practice guidelines recommend using the same ta
Autor:
Anju Nohria, Stephen J. Greene, Lynne W. Stevenson, Gregg C. Fonarow, Javed Butler, Muthiah Vaduganathan, Gaspare Parrinello, Pietro Di Pasquale, Mihai Gheorghiade, Michael H. Alderman, Luna Gargani, Joseph V. Bonventre, Daniele Torres, Salvatore Paterna
Publikováno v:
Heart failure reviewsReference. 26(6)
Despite all available therapies, the rates of hospitalization and death from heart failure (HF) remain unacceptably high. The most common reasons for hospital admission are symptoms related to congestion. During hospitalization, most patients respond
Autor:
Christopher M. O'Connor, Adriaan A. Voors, Javed Butler, Elisabeth Pieske-Kraigher, Mihai Gheorghiade, James E. Udelson, Hani N. Sabbah, Stefan D. Anker, Raymond J. Kim, Gregg C. Fonarow, Savina Nodari, Gerasimos Filippatos, Michele Senni, Muhammad Shahzeb Khan, Burkert Pieske, Jim Carr
Publikováno v:
JOURNAL OF CARDIAC FAILURE, 26(5), 429-437. Churchill Livingstone
Background Elamipretide, a novel mitochondrial modulating agent, improves myocardial energetics; however, it is unknown whether this mechanistic benefit translates into improved cardiac structure and function in heart failure (HF) with reduced ejecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab935080ef08a5e9df254f0c102c4593
http://hdl.handle.net/11379/530060
http://hdl.handle.net/11379/530060
Autor:
Baljash Cheema, Sean P. Collins, Alexandre Mebazaa, Javed Butler, Muthiah Vaduganathan, Mihai Gheorghiade, Joyce N. Njoroge, Ovidiu Chioncel, Stephen J. Greene, Andrew P. Ambrosy
Publikováno v:
Heart Failure Reviews. 23:597-607
Heart failure is a complex disease process, the manifestation of various cardiac and noncardiac abnormalities. General treatment approaches for heart failure have remained the same over the past decades despite the advent of novel therapies and monit